Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

V. Rivera · SciRah

Researcher profile · Semantic Scholar

V. Rivera

Share profile

V. Rivera — researcher profile on SciRah

h-index: 49
Works: 243
Citations: 13K

Most-cited papers

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Wei‐Sheng Huang, Shuang-Ying Liu, D. Zou, Mathew P. Thomas +30 more
2016Journal of Medicinal Chemistry342 citations Open access
Semantic Scholar
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
S. Gettinger, L. Bazhenova, C. Langer, R. Salgia +12 more
2016The Lancet Oncology336 citations
Semantic Scholar
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Sen Zhang, R. Anjum, R. Squillace, S. Nadworny +23 more
2016Clinical Cancer Research297 citations Open access
Semantic Scholar
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
J. Lipton, C. Chuah, A. Guerci-Bresler, G. Rosti +22 more
2016The Lancet Oncology245 citations
Semantic Scholar
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients
A. Garner, J. Gozgit, R. Anjum, S. Vodala +16 more
2014Clinical Cancer Research151 citations Open access
Semantic Scholar
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.
F. Gonzalvez, S. Vincent, T. Baker, A. Gould +22 more
2021Cancer Discovery139 citations
Semantic Scholar
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
M. Deininger, J. Hodgson, N. Shah, J. Cortes +17 more
2016Blood96 citations Open access
Semantic Scholar
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors
T. Baker, S. Nerle, J. Pritchard, Bo-Yang Zhao +3 more
2015OncoTarget75 citations Open access
Semantic Scholar
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
W. Parker, D. Yeung, A. Yeoman, Haley K Altamura +7 more
2016Blood68 citations Open access
Semantic Scholar
Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).
D. Camidge, L. Bazhenova, R. Salgia, C. Langer +12 more
201564 citations
Semantic Scholar
Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
J. Lipton, C. Chuah, A. Guerci-Bresler, G. Rosti +22 more
201459 citations
Semantic Scholar
Current Advances in Pediatric Onset Multiple Sclerosis
K. Fisher, Fernando X. Cuascut, V. Rivera, G. J. Hutton
2020Biomedicines58 citations Open access
Semantic Scholar
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
J. Gozgit, R. Squillace, M. Wongchenko, David P. Miller +6 more
2013Cancer Chemotherapy and Pharmacology55 citations
Semantic Scholar
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
J. Siaw, H. Wan, K. Pfeifer, V. Rivera +3 more
2016OncoTarget50 citations Open access
Semantic Scholar
Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Han Han, Shuai Li, Ting Chen, Michael L. Fitzgerald +25 more
2021Cancer Research42 citations Open access
Semantic Scholar
Access and barriers to MS care in Latin America
V. Rivera, M. Macías
2017Multiple Sclerosis Journal - Experimental, Translational and Clinical41 citations Open access
Semantic Scholar
Status of the neuromyelitis optica spectrum disorder in Latin America.
V. Rivera, F. Hamuy, Verónica Rivas, F. Gracia +60 more
2021Multiple Sclerosis and Related Disorders40 citations Open access
Semantic Scholar
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
M. Mita, E. Poplin, C. Britten, W. Tap +10 more
2013Annals of Oncology40 citations Open access
Semantic Scholar
Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias
Michael W. Schmitt, Justin R. Pritchard, Scott M. Leighow, Bella I. Aminov +6 more
2018Clinical Cancer Research36 citations Open access
Semantic Scholar
Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models
F. Gonzalvez, Xiaotian Zhu, Wei‐Sheng Huang, T. Baker +22 more
201628 citations
Semantic Scholar
Clinical impact of dose modification and dose intensity on response to ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.
A. Hochhaus, J. Pinilla-Ibarz, Dong-Wook Kim, P. le Coutre +16 more
201428 citations
Semantic Scholar
Multiple sclerosis care in Latin America
V. Rivera, M. T. Medina, R. Durón, M. Macías
2014Neurology26 citations Open access
Semantic Scholar
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL
N. Short, H. Kantarjian, R. Kanagal-Shamanna, K. Sasaki +16 more
2020Blood Cancer Journal25 citations Open access
Semantic Scholar
Discovery of Mobocertinib, a Potent, Oral Inhibitor of EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer.
Wei‐Sheng Huang, Feng Li, Yongjin Gong, Yun Zhang +29 more
2022Bioorganic & Medicinal Chemistry Letters23 citations Open access
Semantic Scholar
RET fusions observed in lung and colorectal cancers are sensitive to ponatinib
J. Gozgit, Tzu-Hsiu Chen, Youngchul Song, Scott D. Wardwell +6 more
2018OncoTarget23 citations Open access
Semantic Scholar
PHASE 2 STUDY OF PONATINIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS: EFFICACY, SAFETY, AND IMPACT OF LIQUID BIOPSY AND OTHER BIOMARKERS
S. George, M. von Mehren, J. Fletcher, Jichao G Sun +7 more
2022Clinical Cancer Research22 citations Open access
Semantic Scholar
Multiple Sclerosis in Latin Americans: Genetic Aspects
V. Rivera
2017Current Neurology and Neuroscience Reports20 citations
Semantic Scholar
Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines
V. Rivera
2018Biomedicines19 citations Open access
Semantic Scholar
Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.
S. Gettinger, Sen Zhang, J. Hodgson, L. Bazhenova +15 more
201617 citations
Semantic Scholar
Comprehensive Analysis Of The In Vitro Potency Of Ponatinib, and All Other Approved BCR-ABL Tyrosine Kinase Inhibitors (TKIs), Against a Panel Of Single and Compound BCR-ABL Mutants
A. Schrock, Tzu-Hsiu Chen, T. Clackson, V. Rivera
201317 citations
Semantic Scholar
EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.
J. Lipton, C. Chuah, A. Guerci-Bresler, G. Rosti +15 more
201416 citations
Semantic Scholar
Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events
V. Rivera, J. Pritchard, F. Gonzalvez, T. Baker +2 more
201415 citations
Semantic Scholar
Neuromyelitis Optica Spectrum Disorder in Central America and the Caribbean: A Multinational Clinical Characterization Study
F. Gracia, D. Ramírez, Alexander Parajeles-Vindas, Alejandro Díaz +33 more
2022Neurology International12 citations Open access
Semantic Scholar
Research priorities in multiple sclerosis in Latin America: A multi-stakeholder call to action to improve patients care: Research priorities in MS in LATAM.
J. Rojas, Edgar Carnero Contentti, P. Abad, A. Aguayo +31 more
2021Multiple Sclerosis and Related Disorders12 citations Open access
Semantic Scholar
Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial
A. Hochhaus, J. Cortes, Dong-Wook Kim, J. Pinilla-Ibarz +21 more
201512 citations
Semantic Scholar
Ponatinib Efficacy and Safety in Patients with the T315I Mutation: Long-Term Follow-up of Phase 1 and Phase 2 (PACE) Trials
M. Mauro, J. Cortes, A. Hochhaus, M. Baccarani +12 more
201412 citations
Semantic Scholar
Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
V. Rivera
2019Neurological Therapeutics11 citations Open access
Semantic Scholar
Abstract 781: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models
Sen Zhang, S. Nadworny, Scott D. Wardwell, Lindsey W. Eichinger +4 more
201511 citations
Semantic Scholar
Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.
M. Talpaz, J. Cortes, H. Kantarjian, N. Shah +11 more
201410 citations
Semantic Scholar
1344PBrigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial
L. Bazhenova, S. Gettinger, C. Langer, R. Salgia +8 more
20179 citations Open access
Semantic Scholar
Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis
M. Macías-Islas, Isaac F. Soria-Cedillo, M. Velázquez-Quintana, V. Rivera +3 more
2013Acta Neurologica Belgica8 citations
Semantic Scholar
Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
M. Talpaz, J. Cortes, H. Kantarjian, N. Shah +11 more
20157 citations
Semantic Scholar
Detection of BCR-ABL1 Compound and Polyclonal Mutants in Chronic Myeloid Leukemia Patients Using a Novel Next Generation Sequencing Approach That Minimises PCR and Sequencing Errors
W. Parker, S. Phillis, D. Yeung, D. Lawrence +9 more
20147 citations
Semantic Scholar
Multiple Sclerosis in Central American and Spanish Caribbean Region: Should it be Recognized as a Public Health Problem?
F. Gracia, B. Armién, V. Rivera
20176 citations
Semantic Scholar
Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results.
C. Langer, S. Gettinger, L. Bazhenova, R. Salgia +9 more
20166 citations
Semantic Scholar
Abstract 2827: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants
Wei‐Sheng Huang, Feng Li, Lisi Cai, Yongjin Xu +12 more
20156 citations
Semantic Scholar
Abstract 2084: Ponatinib is a highly potent inhibitor of activated variants of RET found in MTC and NSCLC .
J. Gozgit, Tzu-Hsiu Chen, T. Clackson, V. Rivera
20136 citations
Semantic Scholar
Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)
M. Deininger, N. Shah, J. Cortes, Dong-Wook Kim +18 more
20136 citations
Semantic Scholar
Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study
A. Hochhaus, J. Cortes, Dong-Wook Kim, J. Pinilla-Ibarz +20 more
20174 citations
Semantic Scholar
Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial
L. Bazhenova, S. Gettinger, C. Langer, R. Salgia +9 more
20164 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Clackson×19
Invite
T. Clackson — researcher profile on SciRah
F. Haluska×15
Invite
F. Haluska — researcher profile on SciRah
J. Cortes×12
Invite
J. Cortes — researcher profile on SciRah
H. Kantarjian×12
Invite
H. Kantarjian — researcher profile on SciRah

×11

Invite

S. Lustgarten — researcher profile on SciRah

Invite

N. Shah — researcher profile on SciRah

Invite

M. Talpaz — researcher profile on SciRah

Scott D. Wardwell×10

Invite

Scott D. Wardwell — researcher profile on SciRah

M. Deininger×10

Invite

M. Deininger — researcher profile on SciRah

N. Narasimhan×9

Invite

N. Narasimhan — researcher profile on SciRah

Invite

F. Guilhot — researcher profile on SciRah

Invite

A. Hochhaus — researcher profile on SciRah